Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $32.29 Average PT from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have earned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $32.29.

A number of brokerages have commented on CPRX. Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Bank of America reissued a "buy" rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Finally, HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC bought a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $27,000. Park Square Financial Group LLC bought a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $29,000. Farther Finance Advisors LLC boosted its stake in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. GAMMA Investing LLC increased its stake in Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $65,000. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

CPRX stock traded down $0.67 on Friday, reaching $22.56. 92,421 shares of the company were exchanged, compared to its average volume of 1,137,708. The stock's fifty day moving average price is $22.62 and its 200 day moving average price is $22.05. The firm has a market capitalization of $2.74 billion, a PE ratio of 19.19, a PEG ratio of 3.31 and a beta of 0.79. Catalyst Pharmaceuticals has a 12 month low of $14.47 and a 12 month high of $26.16.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.